• About
  • Interesting shortcuts
  • Programmes and Partnerships
    • Search
    • European Partnerships
    • EU-Programme-Call
  • Projects
    • Projects
  • Resources
    • Resources
  • www.decubber.com
    • Login
  • Programmes and Partnerships
  • EU-Programme-Call
  • Horizon 2020
  • H2020-EU.3. SOCIETAL CHALLENGES
  • H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
  • H2020-EU.3.1.7. Innovative Medicines Initiative 2 (IMI2)
  • H2020-EU.3.1.7.0. Cross-cutting call topics
  • H2020-JTI-IMI2-2018-16-single-stage

H2020-JTI-IMI2-2018-16-single-stage

Mapped projects (5)
  • IMI2-2018-16-01 Progress new assets (one pre-new molecular entity (preNME) and one first-time-in-human (FTIH) start) for TB that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
    (1)
  • IMI2-2018-16-02 Progress novel assets (one FTIH start) for non-tubercular mycobacteria (NTM) that may act synergistically with bedaquiline and cytochrome bc drugs
    (1)
  • IMI2-2018-16-04 Determination of gepotidacin levels in tonsils and prostatic tissue
    (1)
  • IMI2-2018-16-06 Functional Ethionamide boosters: a novel combination for tuberculosis therapy
    (1)
  • IMI2-2018-16-07 Intravenous treatments of serious infections (urinary tract infections, intra-abdominal infections & hospital-acquired pneumonia/ventilator associated pneumonia) caused by Gram(-) bacteria (Enterobacteriaceae +/- Pseudomonas and/or Acinetobacter)
    (1)
Powered by Chris Decubber BV